Our reporters bring you news and highlights from BIO’s in-person and virtual events.
The tap is opening up for venture capital in the biotech industry. Venture investment in biotech jumped 23% year-over-year in 2025 to $23 billion, […]
BIO 2026: How biotechs break the $100M barrier in funding rounds Read More »
Listening to people’s concerns about vaccines is key to helping them regain trust, according to experts promoting the need for life-saving immunizations. “We’ve all
BIO 2026: To restore trust in vaccines, listen to everyone’s concerns Read More »
“CAR-T cell therapies are remarkable drugs and are the gold standard for patients,” said Rachel Haurwitz, PhD, President & CEO of Caribou Biosciences. These
BIO 2026: Realizing the promise of CAR-T cell therapies Read More »
While the U.S. Food and Drug Administration (FDA) has faced significant change in recent years, industry leaders and agency officials alike say there are
BIO 2026: FDA leaders discuss restoring workforce, institutional knowledge Read More »
Industry leaders at BIO 2026 discussed the proposed PDUFA VIII next steps. After a year of discussion with the industry and 127 meetings with
BIO 2026: Industry PDUFA negotiators describe their agreement with FDA Read More »
Experts at the BIO International Convention examine the growth of the 340B drug pricing program, duplicate discounts, patient access, and calls for greater transparency.
BIO 2026: 340B faces growing calls for transparency, patient-focused reform Read More »
From sickle cell disease to multiple sclerosis and childhood leukemia, patients and advocates reflected on becoming pioneers in therapies that are changing medicine.
BIO 2026: ‘I am alive today because of biotech’ Read More »
At a time when U.S. biotech leadership is being challenged, the patent system that enables life-saving innovations is beset by a toxic stew of
BIO 2026: Biotech threatened by pressures on patent protection Read More »
Industry and government leaders at BIO 2026 said stronger biotechnology policy, regulatory modernization, and public-private partnerships are essential to maintaining U.S. leadership in biotech
BIO 2026: American biotech leadership protects patients and national security Read More »
What started as a conversation, in a bar, written on a napkin in 1976, between biochemist Dr. Herbert W. Boyer and investor Robert A.
After 50 years of biotech, can AI help answer the next impossible question? Read More »
